Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | GENERAL COUNSEL | March 18, 2025 | March 20, 2025 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | GC & Chief Compliance Officer | March 17, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date March 18, 2025 · Filed March 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,219 |
Reported balance
After 2025-03-18 transaction · row 1
1 source rowRow 1 · 2025-03-18 · Sale · Disposed 353 · Balance 64,219 F1: These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units ("RSUs"). Such "sale to cover" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $3.14 to $3.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units ("RSUs"). Such "sale to cover" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $3.14 to $3.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Milestone Pharmaceuticals Inc.
Report date March 17, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2036-01-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-17 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: One-fourth (1/4th) of the shares subject to the option vest on January 19, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the option vest on January 19, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2025 Filed Mar 20, 2025 18:47 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 353 | $3.18 | $1,122.29 |
DisclosureSEC source: 0000905148-25-000985 · form4.xml · nonDerivative · entry 1 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,219 F1 · kind: These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units ("RSUs"). Such "sale to cover" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $3.14 to $3.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:49 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000905148-25-000963 · form4.xml · derivative · entry 2 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2035-03-13 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest on March 14, 2026, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:49 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 23,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000963 · form4.xml · nonDerivative · entry 1 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,572 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 14, 2026, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 16:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 4,466 | $4.54 | $20,271.62 |
DisclosureSEC source: 0000905148-25-000092 · form4.xml · nonDerivative · entry 1 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,447 F1 · kind: These shares were sold to cover tax withholding due upon vesting of previously granted restricted stock units. Such "sale to cover" was automatically effected to satisfy tax withholding obligations and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:20 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 15,625 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-24-008638 · form4-03192024_100311.xml · derivative · entry 2 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2034-03-14 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest on March 15, 2025, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:20 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 3,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008638 · form4-03192024_100311.xml · nonDerivative · entry 1 Sandoval David I. · CIK 0002012430 · GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,913 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 15, 2025, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.